uniQure (NASDAQ:QURE) Stock Price Down 9.2% Following Insider Selling

Shares of uniQure N.V. (NASDAQ:QURE) traded down 9.2% on Monday following insider selling activity. The stock traded as low as $23.23 and last traded at $22.9860. 369,864 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 1,691,101 shares. The stock had previously closed at $25.32.

Specifically, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

Several research firms have issued reports on QURE. Stifel Nicolaus lowered their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. HC Wainwright decreased their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a research report on Wednesday. Guggenheim boosted their target price on uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research note on Sunday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $60.82.

uniQure Stock Up 4.0%

The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock has a 50-day simple moving average of $24.98 and a two-hundred day simple moving average of $27.69. The firm has a market cap of $1.39 billion, a PE ratio of -5.09 and a beta of 0.68.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. Analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in QURE. Jefferies Financial Group Inc. bought a new position in shares of uniQure during the 2nd quarter valued at $29,217,000. JPMorgan Chase & Co. grew its stake in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after buying an additional 1,491,486 shares during the last quarter. Fred Alger Management LLC bought a new position in shares of uniQure during the third quarter valued at about $75,320,000. Sofinnova Investments Inc. increased its holdings in shares of uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after buying an additional 1,012,585 shares during the period. Finally, Avoro Capital Advisors LLC lifted its stake in shares of uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after acquiring an additional 819,444 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.